Germany has standardized the access process of innovative drugs to medical insurance through a series of policies, which not only improves the accessibility of innovative drugs for patients, but also reduces the payment pressure of medical insurance funds. There are many aspects worth learning from in this process for China. The access mechanism for innovative drugs in China has always been in the exploration and development stage. Based on the entire process of medical insurance access for innovative drugs, it summarizes its medical insurance access mechanism in Germany, including regulatory organizational structure, medical insurance ac- cess and payment process, and price adjustment mechanism for new indications. At the same time, considering the national conditions of innovative drug access in China, it is recommended that China introduce innovative drug negotiation and arbitration mechanism, payment mode transition mechanism, add a weighted average algorithm mechanism for indication prices to provide international practi- cal experience for China’s current innovative drug access and payment system.